Feb 6, 2023 7:00 am EST NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023
Feb 6, 2023 7:00 am EST RaDaR® Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
Nov 21, 2022 7:00 am EST RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
Nov 18, 2022 9:20 am EST NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
Nov 7, 2022 4:35 pm EST NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
Oct 28, 2022 7:00 am EDT NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
